At a glance
ClinicalIndex Comparison RecordN/ACompleted· 65 enrolled
Drug / intervention
The DyaMX Devicedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Feasibility of Endoscopic Application of a Novel Therapy for Duodenal Mucosal Regeneration in the Treatment of Type II Diabetes
In Brief
A clinical study evaluating The DyaMX Device for Type 2 Diabetes. Completed, enrolled 65 participants across 2 sites.
Detailed Summary
This is an open-label study to assess the safety and feasibility of the DyaMX device for endoscopic duodenal mucosal regeneration in individuals with type 2 diabetes inadequately controlled on glucose-lowering medications.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesAustralia
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedJan 2021
Enrollment StartApr 2021
Primary CompletionMar 2024
Study CompletionDec 2024
TodayJul 2026
First PostedJan 27, 2021
Enrollment StartApr 20, 2021
Primary CompletionMar 1, 2024
Study CompletionDec 22, 2024
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 5.4 years ago
Interventions
The DyaMX Devicedevice
The DyaMX device is designed to induce duodenal mucosal regeneration using pulsed electric field. The DyaMX procedure is a non-surgical, endoscopic procedure.